biostudies-literatureUnknown12(4)Shi Y<h4>Background</h4>Pemetrexed plus platinum alone is the conventional first-line therapy for locally advanced metastatic nonsquamous non-small cell lung cancer (NSCLC) without targetable genetic aberrations. The ORIENT-11 trial revealed that sintilimab + pemetrexed plus platinum could yield more survival benefits for patients with nonsquamous NSCLC. The present study aimed to assess the cost-effectiveness of sintilimab + pemetrexed plus platinum <i>vs.</i> that of pemetrexed plus platinum alone as the first-line therapy for patients with nonsquamous NSCLC to inform clinically rational drug use and provide a basis for medical decision-making.<h4>Methods</h4>A partitioned survival model was created to evaluate the cost-effectiveness of two groups from the perspective of the healthcare systemTranslational cancer research928-938https://www.ebi.ac.uk/biostudies/studies/S-EPMC10175008biostudies-literatureComparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer.PMC10175008Li GLi YQian DBo MJia BChen WZhang MShi JDai YShi YfalseComparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer.<h4>Background</h4>Pemetrexed plus platinum alone is the conventional first-line therapy for locally advanced metastatic nonsquamous non-small cell lung cancer (NSCLC) without targetable genetic aberrations. The ORIENT-11 trial revealed that sintilimab + pemetrexed plus platinum could yield more survival benefits for patients with nonsquamous NSCLC. The present study aimed to assess the cost-effectiveness of sintilimab + pemetrexed plus platinum <i>vs.</i> that of pemetrexed plus platinum alone as the first-line therapy for patients with nonsquamous NSCLC to inform clinically rational drug use and provide a basis for medical decision-making.<h4>Methods</h4>A partitioned survival model was created to evaluate the cost-effectiveness of two groups from the perspective of the healthcare system2023-01-01T00:00:00Z2023 Apr2025-04-04T13:51:28.969Z2025-04-04T13:51:28.969ZS-EPMC101750083718065310.21037/tcr-22-2030